CA2632032C - Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees - Google Patents

Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees Download PDF

Info

Publication number
CA2632032C
CA2632032C CA2632032A CA2632032A CA2632032C CA 2632032 C CA2632032 C CA 2632032C CA 2632032 A CA2632032 A CA 2632032A CA 2632032 A CA2632032 A CA 2632032A CA 2632032 C CA2632032 C CA 2632032C
Authority
CA
Canada
Prior art keywords
ifn
infection
age
individual
smokers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2632032A
Other languages
English (en)
Other versions
CA2632032A1 (fr
Inventor
Donna Davies
Sarah Margaret Puddicombe
Soo-Wei Foo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synairgen Research Ltd
Original Assignee
Synairgen Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synairgen Research Ltd filed Critical Synairgen Research Ltd
Priority to CA2632032A priority Critical patent/CA2632032C/fr
Publication of CA2632032A1 publication Critical patent/CA2632032A1/fr
Application granted granted Critical
Publication of CA2632032C publication Critical patent/CA2632032C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilisation de linterféron bêta (IFN- .bêta.) et/ou IFN-.lambda. pour le traitement dune infection à rhinovirus (RV) chez les personnes âgées, en particulier les personnes âgées qui sont ou ont été des fumeurs à long terme, plus particulièrement ceux qui présentent un historique clinique dinfections à RV récurrentes, et qui peuvent avoir dautres affections médicales, comme des troubles cardiaques ou circulatoires, et qui sont susceptibles de souffrir de complications graves ou de mortalité élevée à la suite dune pauvre habilité innée à combattre une telle infection virale.
CA2632032A 2007-05-18 2008-05-16 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees Active CA2632032C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2632032A CA2632032C (fr) 2007-05-18 2008-05-16 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002589613A CA2589613A1 (fr) 2007-05-18 2007-05-18 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees
CA2,589,613 2007-05-18
CA2632032A CA2632032C (fr) 2007-05-18 2008-05-16 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees

Publications (2)

Publication Number Publication Date
CA2632032A1 CA2632032A1 (fr) 2008-11-18
CA2632032C true CA2632032C (fr) 2016-01-12

Family

ID=40030413

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002589613A Abandoned CA2589613A1 (fr) 2007-05-18 2007-05-18 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees
CA2632032A Active CA2632032C (fr) 2007-05-18 2008-05-16 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002589613A Abandoned CA2589613A1 (fr) 2007-05-18 2007-05-18 Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees

Country Status (1)

Country Link
CA (2) CA2589613A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55154B1 (sr) 2010-03-12 2017-01-31 Synairgen Res Ltd Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom

Also Published As

Publication number Publication date
CA2632032A1 (fr) 2008-11-18
CA2589613A1 (fr) 2008-11-18

Similar Documents

Publication Publication Date Title
US8273342B2 (en) Anti-virus therapy for respiratory diseases
US20210361688A1 (en) System, method and use of a certain medication for reducing viral replication in the airways mucosae
Kan-o et al. Human metapneumovirus infection in chronic obstructive pulmonary disease: impact of glucocorticosteroids and interferon
KR102910416B1 (ko) 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
US7871603B2 (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP5172679B2 (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
CA2632032C (fr) Utilisation de l'interferon-beta et/ou de l'interferon-lambda pour traiter les infections a rhinovirus chez les personnes agees
Yamini et al. Drug repositioning in the treatment Of Covid-19
WO2021253647A1 (fr) Utilisation d'un inhibiteur de petites molécules dans le traitement de la pneumonie virale respiratoire
Higgins et al. Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers
CN101365474B (zh) 用于治疗呼吸道疾病的干扰素λ疗法
Mamber et al. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? mSphere 5, e00288-20
Iyer et al. Inhaled statins to combat COVID-19–prophylactic and treatment approach
Tian et al. Remdesivir: an early repurposed RNA-dependent RNA polymerase inhibitor for treating COVID-19
KR102945285B1 (ko) 잔탄검 또는 후코이단을 포함하는 항인플루엔자 바이러스용 조성물
WO2022166885A1 (fr) Interféron supercomposé recombinant (rsifn-co) pour le traitement de patients atteints de la covid-19 avec ou sans symptômes
Rhodes et al. Opinion/Hypothesis| Therapeutics and Prevention Could Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? Stephen W. Mamber1, Steven Krakowka2, Jeffrey Osborn3, Lloyd Saberski4, Ryan
Wronski et al. Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice
Yadav et al. CONFLUENCE OF RESPIRATORY CHALLENGES: INVESTIGATING THE RELATIONSHIP BETWEEN ASTHMA, ALLERGIES AND COVID-19
JP2024506803A (ja) 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法
CN118743667A (zh) 一种预防呼吸道病毒感染的鼻用制剂
CN121868284A (zh) 用于防治新型冠状病毒感染的药物组合物
CN116249545A (zh) 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化
HK40029346B (en) Use of a small molecule inhibitor for treatment of respiratory viral pneumonia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130514

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260316